Andrew Smolenski, MD
Pain Medicine · Centennial, CONPI 1407907785
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $794 and has fallen 76.4% since, to $188 in 2025. That places this record below the midpoint for pain medicine clinicians in CO, where the typical reported total is $2,943.
Across 91 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$305
- Nevro Corp.$287
- Medtronic$212
- Globus Medical$188
- Si-bone, Inc.$146
- Scilex Pharmaceuticals Inc.$95
- plus $716 from 20 others
What the payments were for
- Food & beverage$1,949100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $305 |
| Nevro Corp. | 16 | $287 |
| Medtronic(2 entities) | 4 | $212 |
| Globus Medical | 4 | $188 |
| Si-bone, Inc. | 1 | $146 |
| Scilex Pharmaceuticals Inc. | 6 | $95 |
| Lilly USA, LLC | 5 | $83 |
| Abbott | 3 | $75 |
| Novartis | 4 | $66 |
| Amgen | 3 | $59 |
| Collegium Pharmaceutical, Inc. | 4 | $58 |
| Sentynl Therapeutics, Inc. | 4 | $52 |
| Arbor Pharmaceuticals, Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Pfizer | 2 | $30 |
| Boston Scientific | 2 | $30 |
| SPR Therapeutics, Inc | 1 | $27 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Painteq LLC | 1 | $26 |
| Bausch Health US, LLC | 1 | $25 |
| Biodelivery Sciences International, Inc. | 2 | $22 |
| Lundbeck LLC | 1 | $20 |
| Shionogi Inc | 1 | $14 |
| Pacira Therapeutics, Inc. | 1 | $13 |
| Fidia Pharma USA Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$151
- iFuse Implant$146
- Senza$130
How this compares
$1,949 in reported general payments places this provider in the 40th percentile of 96 pain medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HorizantGabapentin Enacarbil | 29 | $62,931 |
| BelbucaBuprenorphine Hcl | 68 | $54,984 |
| Nucynta ErTapentadol Hcl | 22 | $39,211 |
| OxycontinOxycodone Hcl | 50 | $36,276 |
| Buprenorphine | 118 | $30,658 |
| UbrelvyUbrogepant | 17 | $26,387 |
| NucyntaTapentadol Hcl | 25 | $23,709 |
| Xtampza ErOxycodone Myristate | 34 | $21,672 |
| BotoxOnabotulinumtoxina | 14 | $16,998 |
| MovantikNaloxegol Oxalate | 38 | $15,664 |
| GraliseGabapentin | 11 | $14,903 |
| QuliptaAtogepant | 12 | $12,792 |
| Hydrocodone Bitartrate ErHydrocodone Bitartrate | 21 | $11,409 |
| Lidocaine | 57 | $10,783 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Nucynta, Xtampza Er | $58 | $139,575149 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $34 | $62,93129 claims |
| AbbVieUbrelvy, Botox, Qulipta | $305 | $56,17743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 96 pain medicine providers in Colorado.
Other pain medicine in Centennial
- Robert MoghimGolden$273K
- Jack RentzGreenwood Village$264K
- Donald BernardiniEnglewood$102K
- Haley BurkeAurora$55K
- Amar PatelThornton$47K
- David ColumbusLoveland$30K
- Matthew PouliotFort Collins$26K
- Justin MerkowEnglewood$24K
- Daniel FeldmanBroomfield$18K
- Steven WrightWheat Ridge$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.